Abstract-A common intronic polymorphism, (Ϫ1332 G/A) of the angiotensin type-2 receptor gene, located on the X-chromosome, has been reported to be functional. The aim of our study was to evaluate this polymorphism for an association with left ventricular hypertrophy. Left ventricle (LV) mass was measured in 197 patients with systemic hypertension and 60 normal volunteers using a 1.5-Tesla Philips MRI system. Genotyping was performed using a restriction enzyme digestion of an initial 310-bp polymerase chain reaction product that included the angiotensin type-2 (Ϫ1332 G/A) locus. The mean LV mass index for the male patients was 94.3Ϯ19.6 g/m 2 (nϭ125) and for the female patients was 71.2Ϯ12.0 g/m 2 (nϭ72). Seventy-three (37.1%) of all patients had an elevated LV mass index, defined as the mean LV mass index for normal volunteers plus 2 SD (males 77.8Ϯ9.1 g/m 2 , nϭ30; females 61.5Ϯ7.5g/m 2 , nϭ30). Comparison of LV mass index of the A_/AA genotype (mean LV mass indexϭ82.4Ϯ21.1 g/m 2 ; nϭ123) against that of the G_/GG genotype (mean LV mass indexϭ88.1Ϯ19.0 g/m 2 ; nϭ89) as a continuous variable was significant by ANOVA (Pϭ0.044).
T he angiotensin II type-2 (AT 2 ) receptor gene is located on the X-chromosome and its structure and nucleotide sequence in humans was described in 1995. 1 It consists of 3 exons and 2 introns, with the entire open reading frame of the AT 2 receptor located on exon 3. A commonly occurring intronic polymorphism has recently been described at a lariat branch-point in intron 1. 2, 3 Its position, described relative to the translation initiation site of the human AT 2 receptor gene, is (Ϫ1332), 2 although it has also been previously described by others 3 as (ϩ1675). In our studies, we use the former nomenclature. It is located 29 bp before exon 2, close to the region that is important for transcriptional activity. 4 Human mRNA studies show that subjects with the G allele have exon 2 missing and that the amount of this abnormally spliced mRNA was markedly reduced. This confirms the functional significance of this point mutation. In the same article, the polymorphism was reported to be associated with congenital anomalies of the kidney and urinary tract in men. 2 Furthermore, Schmieder et al have recently reported a significantly higher left ventricular (LV) mass, measured by M-mode echocardiography, in young mildly hypertensive males with the ϩ1675 A genotype in a study of 120 subjects. 5 However, the accuracy and the reproducibility of M-mode echocardiography, particularly in patients with left ventricular hypertrophy (LVH), have been debated. 6 -8 More recently, cardiac magnetic resonance imaging (MRI) has been used successfully to obtain a more precise and reproducible measure of LV mass in such studies. 9, 10 It is calculated that the number of subjects needed for such studies using cardiac MRI is as little as one-tenth the number required to perform the same study using echocardiography. 11, 12 The AT 2 receptor is thought to oppose the growth promoting effect of the angiotensin II type-1 (AT 1 ) receptor. Moreover, the balance of AT 1 and AT 2 receptors seems to be important in determining both vascular and cardiac remodeling. 13 Studies show that stimulation of the AT 2 receptor is associated with inhibition of growth of vascular smooth muscle cells and apoptosis. 14 It has also been shown to inhibit growth of cardiomyocytes and fibroblasts. 15 In 2 studies of AT 2 knockout mice, LVH did not develop in response to pressure overload, to being induced by constricting the abdominal aorta, or by the infusion of angiotensin II. 16, 17 An obligatory role of AT 2 receptor in the development of cardiac hypertrophy was inferred by the authors. To the contrary, Wu et al found that aortic banding caused cardiac hypertrophy in both AT 2 ϩ and AT 2 Ϫ mice to a similar degree and that coronary arterial thickening and perivascular fibrosis were more exaggerated in AT 2 Ϫ mice. 18 It is known that receptor subtype redistribution occurs in LVH with AT 1 subtype downregulation, resulting in marked increase of the proportion of AT 2 receptor. 19 This suggests a key modulating role for the AT 2 receptor in the development of LVH. The clinical implication is that regression of hypertension induced LVH by AT 1 receptor blockers may in part be caused by unopposed antigrowth effect of angiotensin II mediated via the AT 2 receptor. 20 The aim of our study was to evaluate the AT 2 receptor gene polymorphism (Ϫ1332 G/A) for an association with LVH in patients with systemic hypertension. LV mass is measured precisely using cardiac MRI.
Methods

Patients and Volunteers
Sixty normal volunteers (30 men) were recruited to establish a normal range for cardiac MRI LV volumes and mass 21 as well as the frequency of the AT 2 receptor (Ϫ1332 G/A) polymorphism in a normal population. Two hundred five patients with systemic hypertension were recruited from cardiology outpatient clinics; 85% of the patients were known to have a history of systemic hypertension. The remaining patients were newly referred with the diagnosis of hypertension and were included in the study if they had 2 sitting blood pressure (BP) readings of systolic Ն160 mm Hg and/or diastolic BP Ն100 mm Hg. We excluded patients with a history of valvular heart disease, previous myocardial infarcts, or arrhythmias. Written informed consent was obtained from all subjects and the local ethics committee approved the study.
Imaging Methods
MRI studies were performed on a 1.5-Tesla Philips Intera CV MRI system equipped with Master gradients using a 5-element cardiac phased-array receiver coil and vectorcardiographic ECG synchronization; 10 to 14 short-axis slices, parallel to the mitral valve, covering the heart were acquired using a turbo gradient echo pulse sequence (repetition timeϭ8.8 ms, echo timeϭ5.2 ms, flip angleϭ35°).
Image analysis was performed off-line using commercially available analysis software (MASS; Medis, Leiden, the Netherlands). The LV mass was measured at end-diastole for each slice (Figure 1 ). In all data sets, one experienced observer manually traced the endocardial and epicardial contours of the LV. Two papillary muscles were outlined separately, excluded from the volume, and included in the mass. LV mass was calculated as LV massϭ1.05ϫ(epicardial volumeϪendocardial volume).
Laboratory Methods
After genomic DNA extraction, primers 5Ј AGA GAT CTG GTG CTA TTA CG 3Ј and 5Ј CAC TTG AAG ACT TAC TGG TTG 3Ј (Invitrogen) were used to amplify a 310-bp DNA fragment between intron 1 and exon 2 including the A/G polymorphism. Polymerase chain reactions (PCR) were performed at 95°C for 15 minutes to activate the AmpliTaq Gold enzyme (Applied Biosystems), followed by 35 cycles of: 95°C for 30 seconds, 42°C for 30 seconds, and 72°C for 45 seconds. The product (5 L) was digested for Ͼ3 hours with 5 U of HYP 188 III (New England Biolabs), which cuts the G but not the A allele, then subjected to gel electrophoresis (2% agarose) for genotyping ( Figure 2 ). The AT 2 receptor G allele gives 2 fragments of 104 and 206 bp, and the AT 2 receptor A allele yields a single undigested 310-bp fragment. Genotyping was found to be accurate when confirmed by direct DNA sequencing (BigDye Terminator v3.1 Cycle Sequencing Kit; ABI PRISM, 3100 Genetic Analyzer) for the first 35 patients ( Figure 2 ).
Statistical Methods
A power calculation was used to calculate the sample size with 95% confidence (type I error rateϭ0.05) and 90% power to detect a 10 g/m 2 difference in LV mass index between the means (with SD of the sample of 19 g/m 2 for men and 9 g/m 2 for women). The numbers required were 154 for men and 30 for women. The number of women was doubled (nϭ60) as heterozygous females were excluded from the analysis because of the inactivation of one of the X-chromosomes in females.
The results were analyzed using SPSS software (SPSS for Windows, version 11.0). Means and SDs were calculated for LV mass indexed to body surface area (BSA). LVH was defined as elevated LV mass index, based on the mean LV mass index for normal volunteers plus 2 SDs. 21 Because angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to influence LV mass regression, we used the test of unpaired proportions to assess for a difference between the A_/AA and G_/GG genotypes (hemizygous males and homozygous females) in drug treatment. We used the Mann-Whitney test to assess for a difference between the means of the doses of those 2 drugs according to genotype. We also used the t test to investigate whether there was a difference in BP measurements between the 2 genotypes. The association of the G_/GG alleles with elevated LV mass index, as a continuous variable, was assessed using analysis of variance (1-way ANOVA). 2 Test was performed to compare the prevalence of A_/AA and G_/GG genotypes, for hemizygous males and homozygous females, based on the presence or absence of LVH.
Results
All 60 healthy volunteers completed the cardiac MRI studies. Their mean age was 43Ϯ12 years, range 20 to 65 years, and they had a mean sitting BP of 123/72 mm Hg. Two of the volunteers did not provide a blood sample and were excluded from the genetic part of the analysis. Of the 205 patients recruited, 8 were excluded because of poor DNA quality. The mean age of the 197 remaining patients was 55.4Ϯ11.4 years (age range 21 to 79 years); 125 (63.5%) were men, and 168 (85.3%) of the hypertensive patients were using antihypertensive medications (Table 1 ). To consider whether there was a difference between the A_/AA and G_/GG genotypes in drug treatment with ACE inhibitors and ARBs, we used the test of unpaired proportions. There was no significant difference between the proportion of the A_/AA genotypes on The mean sitting BP for the patients group was 159/ 93 mm Hg. For those patients who had a 24-hour BP monitor (nϭ159), the group average of the mean 24-hour BP was 141/87 mm Hg. The group average of the daytime BP (based on the 24-hour BP recording) for the same 159 patients was 146/91 mm Hg. Differences in BP measurements between A_/AA and G_/GG genotypes were considered. The F test confirmed that there were no significant differences between the BP variances for the 2 genotypes. We then used the t test to test the hypothesis that there was no difference between the means ( Table 2) .
The mean LV mass indexed to body surface area (BSA) for the male healthy volunteers was 77.8Ϯ9.1 g/m 2 (nϭ30) and for the female healthy volunteers was 61.5Ϯ7.5g/m 2 (nϭ30). 21 For the patients with hypertension, the mean LV mass indexed to BSA for the male patients was 94.3Ϯ19.6 g/m 2 (nϭ125) and for the female patients was 71.2Ϯ12.0g/m 2 (nϭ72). A 2-way ANOVA showed a difference in the mean LV mass according to gender and hypertension status (PϽ0.0001). Seventy-three (37.1%) patients had LVH (20; 27.8% of the female patients and 53; 42.4% of the male patients). The distribution of genotypes among the normal subjects and the subjects with hypertension with and without LVH was calculated ( Figure 3 ). We assessed LV mass index as a continuous variable using data from all subjects. When the A_/AA genotype (mean LV mass indexϭ82.4Ϯ21.1 g/m 2 ; nϭ123) were compared with the G_/GG genotype (mean LV mass indexϭ88.1Ϯ19.0 g/m 2 ; nϭ89), the ANOVA was statistically significant (Pϭ0.044; 95% confidence interval for the difference in means was Ϫ11.3 g/m 2 to Ϫ0.2 g/m 2 ). For the female subjects, the mean LV mass index for AA genotype was 67.6Ϯ12.8 g (nϭ40), and for the GG genotype was 68.4Ϯ9.8 g (nϭ18). For the male subjects, the mean LV mass index for the A haplotype was 89.5Ϯ20.6 g (nϭ83) and for the G haplotype was 93.1Ϯ17.4 g (nϭ71). 2 Test was performed to assess the prevalence of A_/AA and G_/GG alleles between the subjects without LVH (normal volunteers and hypertensives without LVH) and the hypertensive patients with LVH. Heterozygous females were excluded from the analysis because of the inactivation of one of the X-chromosomes in females. The frequency of the G_/GG genotype was found to be higher in the hypertensive patients with LVH (Pϭ0.031). The 2 test was repeated on the females and males separately with Pϭ0.67 and Pϭ0.058, respectively. The 2 test was also performed to assess the prevalence of A_/AA and G_/GG alleles between the normal volunteers and hypertensive patients with LVH. The frequency of the G_/GG genotype was found to be higher in hypertensive patients with LVH than it was for normal volunteers (Pϭ0.023). When the 2 test was also performed to assess the prevalence of A_/AA and G_/GG alleles between the hypertensive patients without LVH and hypertensive patients with LVH, the frequency of the G_/GG genotype was found to be higher in the patients with LVH. (Pϭ0.058) (Figure 3) . 
Discussion
Cardiac MRI provides a spatially defined 3-dimensional data set at multiple levels throughout the heart; hence, the measurement of LV mass does not require geometric assumptions to be made about the LV. The excellent contrast between blood and myocardial tissue and the high resolution mean that the endocardial and epicardial contours are easily defined. MRI measurements of LV mass have been validated in animal studies, 22 shown to be more accurate and reproducible than M-mode and 2-dimensional echocardiography, 8, 23, 24 and is currently accepted as the technique of choice for LV mass measurements. Although M-mode echocardiography is widely used to estimate LV mass, its accuracy is limited, particularly in patients with LVH in whom the geometric assumptions about the structure of the LV may no longer be valid. 6 -8 It is calculated that to perform such studies using echocardiography, one would need 10-times the number of subjects required by cardiac MRI. 11, 12 Our patients all had systemic hypertension that was either previously diagnosed/treated (85.3%) or newly diagnosed/untreated (14.7%). Consequently, the severity of hypertension also varied within this group. We did not consider it either necessary or appropriate to stop antihypertensive medication for the purpose of this study. Continued use of antihypertensive drugs would be expected to have resulted in attenuation of LVH, the severity of which would, in any case, be expected to vary in this group of patients. 25, 26 Nevertheless, similar frequency of use of both ACE inhibitors and ARBs should have ensured that this was not a confounding factor in our observations. If the use of drugs acted as a confounding factor, the effect would have been to make an association between genotype and LV mass more difficult to detect.
We compared the A_/AA genotype (mean LV mass indexϭ82.4Ϯ21.1 g/m 2 ; nϭ123) to the G_/GG genotype (mean LV mass indexϭ88.1Ϯ19.0 g/m 2 ; nϭ89) by ANOVA and found a difference that was statistically significant (Pϭ0.044). A comparison of subjects with LVH to the subjects without LVH revealed a significant excess of the G_/GG genotype (Pϭ0.031). Furthermore, a comparison of the hypertensives with LVH to the normal volunteers revealed a significant excess of the G_/GG genotype (Pϭ0.023). Additional evidence to support the biological validity of our observations is the trend (Pϭ0.058) of excess G_/GG genotype among the hypertensives with LVH when compared with the hypertensives without LVH (Figure 3 ). Our findings suggest that the (Ϫ1332 G) polymorphism of the AT 2 receptor is associated with hypertension related LVH. The LVH observed was present despite the fact that the majority of the patients were using antihypertensive medications. This is of importance because LVH is associated with excess risk of morbidity and mortality. The AT 2 receptor polymorphism might serve as a marker for patients who would benefit from a more aggressive control of BP and/or drugs that block the AT 1 receptor that have been shown to improve outcomes. 20, 27 Previously, Schmieder et al studied LV mass as measured by M-mode echocardiography in 120 healthy male students with normal or mildly elevated BP, reporting an association between the AT 2 receptor (ϩ1675 A/G) polymorphism and LV mass. 5 The overall allele frequency for this study was comparable to our own (Aϭ57% and 
Perspectives
Mutations located in noncoding regions, such as those affecting 5Ј and 3Ј splice sites or branch sites, are often the cause of hereditary disease. 30 The AT 2 receptor gene (Ϫ1332 G/A) intronic polymorphism has been reported to be located at a lariat branch-point in intron 1. Differently spliced AT 2 receptor mRNA species have already been described and shown to be biochemically functional. 2 Elevated LV mass is associated with excess risk of morbidity and mortality. In a prospective study, we have observed a statistical association between the AT 2 (Ϫ1332 G) allele and the presence of LVH in patients with hypertension. Less effective transcription of the AT 2 receptor gene, as a result of the (Ϫ1332 G) polymorphism might be expected to result in reduced AT 2 receptor mediated effects in patients with the G allele. 2 Our results are therefore in keeping with the hypothesis that the AT 2 receptor counteracts the myocardial growth promoting effects of the AT 1 receptor. 14 The AT 2 receptor polymorphism might serve as a marker for patients who would benefit from a more aggressive control of BP and/or drugs that block the AT 1 receptor, either ARBs or ACE inhibitors, because they have been shown to improve outcomes. 20, 27 
